{"url":"https://lda.senate.gov/api/v1/filings/cee8f043-eabf-4989-805a-22729dfaa659/","filing_uuid":"cee8f043-eabf-4989-805a-22729dfaa659","filing_type":"3T","filing_type_display":"3rd Quarter - Termination","filing_year":2021,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/cee8f043-eabf-4989-805a-22729dfaa659/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Karen Blitz","dt_posted":"2021-10-18T11:37:11.340000-04:00","termination_date":"2021-09-30","registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1401 Eye Street, NW","registrant_address_2":"Suite 800","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":314911,"url":"https://lda.senate.gov/api/v1/registrants/314911/","house_registrant_id":39171,"name":"POLSINELLI PC","description":"Law Firm","address_1":"1401 Eye Street, NW","address_2":"Suite 800","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KAREN BLITZ","contact_telephone":"+1 202-783-3300","dt_updated":"2026-07-15T15:35:57.778520-04:00"},"client":{"id":185279,"url":"https://lda.senate.gov/api/v1/clients/185279/","client_id":1004811,"name":"BLUEBIRD BIO","general_description":"Gene therapy company developing treatments for severe and incurable diseases.","client_government_entity":false,"client_self_select":null,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-12-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to the reimbursement of gene therapies; issues related to the Patient Affordability and Efficiency Act.\nS. 2543, Prescription Drug Pricing Reduction Act; issues related to value-based payment\nIssues related to value-based drug pricing and drug pricing in general","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":59931,"prefix":null,"prefix_display":null,"first_name":"ALAN","nickname":null,"middle_name":null,"last_name":"WHEAT","suffix":null,"suffix_display":null},"covered_position":"former Member of Congress from Missouri","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Provide guidance and strategic counsel with regard to regulations and legislation that could impact the gene therapies, drug pricing, and other issues that impact the industry generally, but bluebird bio specifically\nIssues related to gene therapies, drug pricing, and bluebird bio specifically","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":59931,"prefix":null,"prefix_display":null,"first_name":"ALAN","nickname":null,"middle_name":null,"last_name":"WHEAT","suffix":null,"suffix_display":null},"covered_position":"former Member of Congress from Missouri","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}